Skip to content
Calculator
Evidence: HighPeptideNot FDA ApprovedGlycopeptideNot FDA-approvedAntibiotic

Teicoplanin

A glycopeptide antibiotic used widely outside the US

Teicoplanin is a glycopeptide antibiotic closely related to vancomycin, used outside the US for serious Gram-positive infections such as MRSA. A meta-analysis of randomised trials found it as effective as vancomycin with fewer adverse events, including less kidney damage. It has never been approved by FDA.

Used in human trials: 10-12 mg/kg, Every 12 hours for 5 loading doses, Intravenous (Study: loading to reach troughs of 15-30 mg/L (normal kidney function)) Details ↓

Overview

What is it?

Vancomycin and teicoplanin are the two glycopeptides in clinical use for infections caused by invasive beta-lactam-resistant Gram-positive organisms, as a 2009 meta-analysis puts it. Teicoplanin is used outside the US, but an openFDA search of Drugs@FDA finds no US approval, so American clinicians use vancomycin or newer lipoglycopeptides such as dalbavancin, oritavancin and telavancin instead.

A meta-analysis of randomised trials comparing the two found teicoplanin not inferior to vancomycin for efficacy, with significantly fewer total adverse events (risk ratio 0.61), less nephrotoxicity (risk ratio 0.44) and less red man syndrome. Real-world data agree on the kidneys: in matched older patients, nephrotoxicity was 16% on teicoplanin against 32% on vancomycin. In nosocomial pneumonia, pooled trials found linezolid and the glycopeptides, vancomycin or teicoplanin, gave similar clinical cure rates.

Not every comparison favours it. In one hospital's MRSA pneumonia patients, teicoplanin failed far more often than vancomycin, with higher mortality, although vancomycin caused more side effects. As surgical prophylaxis it offered no advantage over a cheaper standard: in prosthetic vascular surgery, infection and mortality were similar to cefazolin.

Getting enough drug into the blood early matters. One study found that reaching trough concentrations of 15 to 30 mg/L required five loading doses at 12-hour intervals in patients with normal kidney function, and patients at or above 15 mg/L tended to respond better (80.9% against 68.6%). Older adults on low-dose regimens were mostly underdosed in the first week, and in children troughs below 10 mg/L halved treatment success. That is why levels are monitored.

0.44
Risk ratio for nephrotoxicity vs vancomycin
Meta-analysis of trials · PMID 19596875
5 doses
Loading doses to reach target troughs
10-12 mg/kg every 12 hours · PMID 24462424
Not FDA
No US approval
Used outside the US
Science

Mechanism of Action

Teicoplanin is a glycopeptide antibiotic, like vancomycin, used against resistant Gram-positive bacteria such as MRSA.

🧱

Cell wall blocked

Like vancomycin, it binds the building blocks of the bacterial cell wall and stops Gram-positive bacteria building it.

🎯

Gram-positive only

Used for MRSA and other beta-lactam-resistant Gram-positive infections, including bacteraemia, pneumonia and catheter infections.

📈

Level-guided

Needs several loading doses to reach target troughs; levels are monitored, especially in older adults, children and kidney impairment.

Evidence

Published Research

Studies of teicoplanin, from their PubMed abstracts.

Human2009

Against vancomycin: meta-analysis

Across randomised trials, teicoplanin was not inferior to vancomycin for efficacy, with fewer total adverse events (RR 0.61), less nephrotoxicity (RR 0.44) and less red man syndrome.

PMID: 19596875
Human2014

Loading doses and trough levels

Five loading doses of 10-12 mg/kg at 12-hour intervals were needed to reach troughs of 15-30 mg/L; patients at 15 mg/L or more tended to respond better (80.9% vs 68.6%), with nephrotoxicity of 1.3% and 3.3% across regimens.

PMID: 24462424
Human2010

Nosocomial pneumonia vs linezolid

Across nine trials (2,329 patients), linezolid and the glycopeptides vancomycin or teicoplanin gave similar clinical cure (RR 1.01) and microbiological eradication.

PMID: 20639754
Human2023

MRSA bacteraemia vs linezolid

A meta-analysis of 5,328 patients found linezolid's effectiveness and adverse events comparable to vancomycin, teicoplanin or daptomycin for MRSA bacteraemia.

PMID: 37107059
Human2013

Nosocomial pneumonia: twelve trials

Across twelve randomised trials of linezolid against vancomycin or teicoplanin, clinical cure did not differ significantly (RR 1.08, p = 0.06), but microbiological eradication was better with linezolid.

PMID: 23568605
Human1999

Prophylaxis in vascular surgery: against cefazolin

Infection rates and mortality were similar with teicoplanin and cefazolin prophylaxis; cefazolin cost far less, and the authors kept it as the drug of choice for clean vascular surgery.

PMID: 10357049
Human2026

Kidneys in older patients

In 186 propensity-matched older patients, nephrotoxicity occurred in 16.1% on teicoplanin against 32.3% on vancomycin; longer exposure and higher baseline creatinine raised the risk.

PMID: 41544845
Human2022

MRSA pneumonia: vancomycin did better

In 116 patients with MRSA pneumonia, clinical failure was 61.3% on teicoplanin against 25.9% on vancomycin and mortality 19.4% against 3.7%, though vancomycin caused more drug changes for side effects (24.1% against 1.6%).

PMID: 35799129
Human2024

Older adults are underdosed

In 204 older patients, two-thirds had suboptimal levels in the first week on mostly low-dose regimens; thrombocytopenia occurred in 31.5%, nephrotoxicity in 12.5% and hepatotoxicity in 4.1%.

PMID: 38831261
Human2026

Standard doses in children

In a paediatric cohort, standard dosing reached target levels early; nearly half of samples exceeded 60 mg/L total, yet no nephrotoxicity was seen, which the authors attribute to normal albumin keeping free drug in range.

PMID: 42208049
Human2023

Lock therapy for port infections

In 22 children with cancer and port-related coagulase-negative staphylococcal bacteraemia, teicoplanin lock therapy saved 72.7% of ports, with cultures clearing in about 4 days.

PMID: 35700426
Review2026

Kidney injury with piperacillin-tazobactam

Across five cohort studies of 908 patients, piperacillin-tazobactam plus teicoplanin was linked to less acute kidney injury than the same drug plus vancomycin (odds ratio 0.52), with no difference in 30-day mortality. The studies were observational.

PMID: 40940625
Review2013

MRSA in Chinese patients

A meta-analysis of 12 studies found teicoplanin and vancomycin similar for clinical cure, microbiological cure and adverse events in MRSA infection.

PMID: 24260299
Review2024

Target levels in children

Across 12 studies and 830 children, troughs under 10 mg/L cut treatment success (50.0% against 95.7%), while troughs under 20 mg/L were linked to less nephrotoxicity.

PMID: 39023364
Dosing

Dosing Data

There is no US label. One study needed five loading doses of 10 to 12 mg/kg every 12 hours to reach target troughs; after that, dosing is guided by trough levels.

Not approved in the US; hospital antibiotic elsewhere. Dosing is individualised by weight, kidney function and trough levels.
ProtocolDoseFrequencyDurationRoute
Study: loading to reach troughs of 15-30 mg/L (normal kidney function) Human studyPMID 2446242410-12 mg/kgEvery 12 hours for 5 loading dosesCourse of infectionIntravenous

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Weight and level-guided
Teicoplanin is dosed per kilogram with loading doses and adjusted by trough levels; this is done by the hospital team.
Open Calculator →
For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

Unknown: we hold no label and no published test that says what forms or vial sizes Teicoplanin is sold in. A vial's own label is a seller's claim, not a source.

Mixing a vial: a worked example

No worked example: none of the doses on this page is a fixed amount in mg or mcg injected under the skin or into a muscle (the routes given are: intravenous). There is no home-mixing step to show. The reconstitution calculator does the arithmetic for any vial.

Source: the route and amount of each dose row in Dosing Data below.

Storage before and after mixing

Unknown: no label or published stability study on file says how to store Teicoplanin, before or after mixing. The mixing guide sets out the general rules, with their sources: keep a mixed vial in the fridge, and use it promptly, as the bacteriostatic water label says of any drug dissolved in it. The 28 days often quoted is the limit for an opened multiple-dose vial from a manufacturer, an outer limit set for sterility, not a time a mixed solution has been shown to keep. Nobody has published how long Teicoplanin stays intact once mixed.

How it is taken

As it was given in human studies: Intravenous (Every 12 hours for 5 loading doses; Study: loading to reach troughs of 15-30 mg/L (normal kidney function)).

For injection technique, sites and needle disposal, see the mixing guide.

Source: Used in human trials: the route and frequency of each row in Dosing Data below.

What to expect, and when

How long it stays in the body: not established by a measurement cited on this entry.

How long the doses were given: Study: loading to reach troughs of 15-30 mg/L (normal kidney function): Course of infection.

When effects appear: unknown; no source on this page gives a time to effect for Teicoplanin. Results reported in the studies are under Published Research.

Source: Used in human trials, the duration of each row in Dosing Data below.

Side effects, and when to stop or get help

From the Side Effects section: Fewer adverse events, less nephrotoxicity and less red man syndrome than vancomycin. Full list and cautions ↓

When to stop or get help: unknown; no label or trial on file sets rules for stopping Teicoplanin. Treat a severe or unexpected reaction as a reason to stop and see a doctor.

Source: the Side Effects section below (“From the studies above”).

Interactions

  • warfarin: PT-INR rose a median 80.9% after teicoplanin was added, against 30.6% with vancomycin, in a retrospective study of 49 patients; monitor INR
  • tacrolimus: both are nephrotoxic; with drug monitoring of each, a 2-fold creatinine rise occurred in 2 of 67 stem cell transplant patients, reversibly

Every peptide's record, with its source: the interaction matrix.

Source: human study, PMID 28674307; human study, PMID 24494811.

Checking what you bought

Unknown: no published independent test of Teicoplanin products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: Not FDA Approved (Not approved by FDA: an openFDA Drugs@FDA search for teicoplanin returned no records (October 3, 2026)). Sport: Not on the 2026 List.

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the studies above.

● Fewer adverse events, less nephrotoxicity and less red man syndrome than vancomycin

Contraindications & Cautions

No US label; it is not approved in the US.

● Used outside the US under local product information
Questions

Frequently Asked Questions

?Is teicoplanin the same as vancomycin?

No, but they are close relatives: both are glycopeptide antibiotics that block cell-wall building in Gram-positive bacteria.

?Is teicoplanin safer than vancomycin?

In a meta-analysis of randomised trials it caused fewer adverse events overall, less kidney damage and less red man syndrome, with similar effectiveness.

?Why isn't teicoplanin available in the US?

It has no FDA approval; Drugs@FDA lists no teicoplanin product. It is used in Europe and elsewhere.

?Why are loading doses used?

Teicoplanin takes time to reach effective blood levels. One study found five loading doses of 10-12 mg/kg at 12-hour intervals were needed to reach trough levels of 15 to 30 mg/L in patients with normal kidney function.

?Is linezolid better than teicoplanin for hospital pneumonia?

Pooled trials found similar clinical cure rates; one analysis of twelve trials found better bacterial eradication with linezolid, without a significant difference in cure.

?What kidney monitoring is needed?

Teicoplanin caused less nephrotoxicity than vancomycin in pooled trials, and in the loading-dose study nephrotoxicity was 1.3% and 3.3% across two regimens, but kidney function still guides dosing.

?Is it kinder to the kidneys than vancomycin?

The evidence points that way. A meta-analysis of randomised trials found less nephrotoxicity (risk ratio 0.44), and in matched older patients kidney injury occurred in 16.1% on teicoplanin against 32.3% on vancomycin.

?Why are blood levels checked?

Because early levels are often too low. Older adults on standard regimens were mostly underdosed in the first week, and in children troughs below 10 mg/L were linked to treatment success of 50% against 95.7% above it.

?Can it treat infected ports?

In 22 children with cancer and port-related staphylococcal bacteraemia, teicoplanin lock therapy saved 72.7% of ports.

Bibliography

References

  1. [fda] US FDA, Drugs@FDA via openFDA: search for generic name teicoplanin returned no records. Read October 3, 2026.
  2. [pubmed] Svetitsky S, et al. "Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis." Antimicrob Agents Chemother, 2009;53(10):4069-79. PMID: 19596875.
  3. [pubmed] Ueda T, et al. "High-dose regimen to achieve novel target trough concentration in teicoplanin." J Infect Chemother, 2014;20(1):43-7. PMID: 24462424.
  4. [pubmed] Kalil AC, et al. "Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis." Crit Care Med, 2010;38(9):1802-8. PMID: 20639754.
  5. [pubmed] Kawasuji H, et al. "Effectiveness and Safety of Linezolid Versus Vancomycin, Teicoplanin, or Daptomycin against Methicillin-Resistant Staphylococcus aureus Bacteremia: A Systematic Review and Meta-Analysis." Antibiotics (Basel), 2023;12(4). PMID: 37107059.
  6. [pubmed] Jiang H, et al. "Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials." Eur J Clin Microbiol Infect Dis, 2013;32(9):1121-8. PMID: 23568605.
  7. [pubmed] Marroni M, et al. "Prospective, randomized, double-blind trial comparing teicoplanin and cefazolin as antibiotic prophylaxis in prosthetic vascular surgery." Eur J Clin Microbiol Infect Dis, 1999;18(3):175-8. PMID: 10357049.
  8. [pubmed] Mohammad S, et al. "Comparative Risk of Acute Kidney Injury with Piperacillin-Tazobactam Plus Teicoplanin Versus Piperacillin-Tazobactam Plus Vancomycin: A Systematic Review and Meta-Analysis." Drug Saf, 2026;49(3):291-302. PMID: 40940625.
  9. [pubmed] Peng Y, et al. "Teicoplanin as an effective alternative to vancomycin for treatment of MRSA infection in Chinese population: a meta-analysis of randomized controlled trials." PLoS One, 2013;8(11):e79782. PMID: 24260299.
  10. [pubmed] Wu J, et al. "Comparative renal safety of teicoplanin versus vancomycin in older patients: a propensity-matched multicenter study." Int J Infect Dis, 2026;164:108399. PMID: 41544845.
  11. [pubmed] Lee JH, et al. "Comparison of mortality and clinical failure rates between vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia." BMC Infect Dis, 2022;22(1):600. PMID: 35799129.
  12. [pubmed] Liu T, et al. "Necessity for higher teicoplanin doses in older adults: a multicenter prospective observational study in China." BMC Geriatr, 2024;24(1):487. PMID: 38831261.
  13. [pubmed] Mariani M, et al. ""Standard" Is More Than Enough: Therapeutic Drug Monitoring Confirms Early Target Attainment of Teicoplanin Regimens in Pediatric Patients." Ther Drug Monit, 2026. PMID: 42208049.
  14. [pubmed] Okur Acar S, et al. "Efficacy of Teicoplanin Lock Therapy in the Treatment of Port-related Coagulase-negative Staphylococci Bacteremia in Pediatric Oncology Patients." J Pediatr Hematol Oncol, 2023;45(1):e17-e20. PMID: 35700426.
  15. [pubmed] Hanai Y, et al. "Optimal Teicoplanin Trough Concentration With Therapeutic Drug Monitoring in Children: A Systematic Review and Meta-analysis." Ther Drug Monit, 2024;46(6):699-709. PMID: 39023364.

Sources & Citations

Studies were read from their PubMed abstracts; no US label exists. Read October 6, 2026.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-10-06